Email updates

Keep up to date with the latest news and content from Journal of Biology and BioMed Central.

Minireview

Exploiting the promiscuity of imatinib

Shun J Lee12 and Jean YJ Wang123*

Author affiliations

1 Department of Medicine and Division of Hematology-Oncology, 3855 Health Sciences Drive, University of California, San Diego, La Jolla, CA 92093, USA

2 Moores Cancer Center, 3855 Health Sciences Drive, University of California, San Diego, La Jolla, CA 92093, USA

3 Division of Biological Sciences, 3855 Health Sciences Drive, University of California, San Diego, La Jolla, CA 92093, USA

For all author emails, please log on.

Citation and License

Journal of Biology 2009, 8:30  doi:10.1186/jbiol134

Published: 15 April 2009

Abstract

The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.